- Home
- EBC vs KNSA Comparison
EBC vs KNSA Comparison
Compare EBC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBC | KNSA |
|---|---|---|
| Founded | 1818 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EBC | KNSA |
|---|---|---|
| Price | $19.86 | $48.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $22.70 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.5M | 464.3K |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 0.29 | 0.27 |
| Revenue | $134,091,000.00 | ★ $677,564,000.00 |
| Revenue This Year | $80.92 | $37.48 |
| Revenue Next Year | $4.44 | $17.87 |
| P/E Ratio | ★ $69.28 | $182.33 |
| Revenue Growth | 19.07 | ★ 60.09 |
| 52 Week Low | $14.10 | $26.27 |
| 52 Week High | $22.58 | $59.87 |
Technical Indicators
Market Signals| Indicator | EBC | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 40.53 |
| Support Level | $19.07 | $40.67 |
| Resistance Level | $20.15 | $49.57 |
| Average True Range (ATR) | 0.37 | 2.05 |
| MACD | 0.03 | -0.90 |
| Stochastic Oscillator | 63.98 | 21.73 |
Price Performance
Historical ComparisonAbout EBC Eastern Bankshares Inc.
Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment: Banking business, which offers a range of banking, lending, savings, and small business offerings, and its wealth management and trust operations.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.